EGFR and neoplasm: Since the ORR was only 1-3% in patients who were treated with regorafenib (22, 23) or TAS102 (24, 25) in third- or later-line setting, our data supported the use of anti-EGFR Ab plus irinotecan in third-line treatment in patients with no prior anti-EGFR Ab before regorafenib or TAS102 regardless of tumor sidedness.